Surgical Design Studios develops purpose-built chyme reinfusion therapies for patients with intestinal failure, utilizing advanced techniques to reduce intestinal losses and enhance gut function. Their solution enables a significant reduction in reliance on parenteral nutrition, facilitating earlier discharge and improved nutritional outcomes for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with intestinal failure often experience significant loss of enteric contents, leading to dehydration, malnutrition, and reliance on parenteral nutrition. Traditional management strategies may not adequately restore gut function or reduce the need for intravenous feeding.
Solution
Surgical Design Studios develops chyme reinfusion therapies designed to reduce intestinal losses and enhance gut function in patients with intestinal failure. Their approach involves reinfusing chyme back into the digestive system, promoting the restoration of gut function and reducing the volume of chyme discarded. This therapy aims to decrease the reliance on parenteral nutrition, facilitate earlier hospital discharge, and improve overall nutritional outcomes for both adult and pediatric patients. By returning enteric contents, the therapy supports the reversal of gut atrophy and inflammation, while also improving liver function and enabling patient mobilization without dependence on an IV pole.
Target Audience
The primary target audience includes adult and pediatric patients experiencing intestinal failure, as well as the clinicians and hospitals managing their care.
Features
- Purpose-built chyme reinfusion systems for adult and pediatric intestinal failure.
- Designed to reduce intestinal losses and promote increased bowel length for absorption.
- Aims to restore gut function by reversing gut atrophy and inflammation.
- Facilitates weaning off parenteral nutrition and a return to oral feeding.
- Supports improved nutritional status and liver function.
- Enables patient mobilization without being tethered to an IV pole.